.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Teva
US Department of Justice
Accenture
Fish and Richardson
Citi
Queensland Health
Boehringer Ingelheim
UBS
Chinese Patent Office

Generated: December 18, 2017

DrugPatentWatch Database Preview

LUSEDRA Drug Profile

« Back to Dashboard

Which patents cover Lusedra, and when can generic versions of Lusedra launch?

Lusedra is a drug marketed by Eisai Inc and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-four patent family members in twenty-five countries.

The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.

Summary for LUSEDRA

US Patents:2
Applicants:1
NDAs:1
Clinical Trials: 8
Drug Prices:see details
DailyMed Link:LUSEDRA at DailyMed
Drug patent expirations by year for LUSEDRA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai IncLUSEDRAfospropofol disodiumSOLUTION;INTRAVENOUS022244-001Dec 12, 2008DISCNNoNo► Subscribe► SubscribeY► Subscribe
Eisai IncLUSEDRAfospropofol disodiumSOLUTION;INTRAVENOUS022244-001Dec 12, 2008DISCNNoNo► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: LUSEDRA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe LUSEDRA ► Subscribe

Non-Orange Book Patents for Tradename: LUSEDRA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,451,776 Water soluble prodrugs of hindered alcohols► Subscribe
7,244,718Water soluble prodrugs of hindered alcohols► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LUSEDRA

Country Document Number Estimated Expiration
Slovenia1102776► Subscribe
Spain2268876► Subscribe
Hungary0200317► Subscribe
Norway330357► Subscribe
Czech Republic20010479► Subscribe
Portugal1102776► Subscribe
Australia769755► Subscribe
Brazil9912853► Subscribe
European Patent Office1102776► Subscribe
Japan4554081► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Accenture
Merck
Covington
Chubb
QuintilesIMS
Dow
Mallinckrodt
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot